Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System

NCT03124875 · View on ClinicalTrials.gov ↗

Study Summary

This pilot study will investigate the safety, effectiveness and feasibility of the LimFlow Stent Graft System for creating an AV fistula in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive approach for the treatment of Critical Limb Ischemia (CLI) in subjects ineligible for conventional endovascular or surgical limb salvage procedures.

Interventions

  • DEVICE LimFlow System

Study Locations (7)

District of Columbia

  • Medstar Washington Hospital Center — Washington D.C.

Hawaii

  • Kaiser Permanente — Honolulu

Michigan

  • Metro Health, University of Michigan — Wyoming

New Mexico

  • New Mexico Heart Institute — Albuquerque

New York

  • Mount Sinai Health System — New York

Ohio

  • University Hospitals Cleveland Medical Center — Cleveland

South Carolina

  • Palmetto Health — Columbia

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2017-07-05
Est. Completion 2021-01-05
Phase NA

Sponsor

LimFlow

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03124875

The ClinicalTrials.gov registry entry for NCT03124875 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LimFlow, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Critical Limb Ischemia appearing as the primary indexed condition, and to 1 intervention — of which LimFlow System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03124875 reports 7 study locations spanning 7 distinct geographic areas — top geographies include District of Columbia, Hawaii, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03124875 about?

NCT03124875 is a clinical study titled "PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System". This pilot study will investigate the safety, effectiveness and feasibility of the LimFlow Stent Graft System for creating an AV fistula in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive approach for the treatment of Critical Limb Ischemia (CLI) in subjects inelig...

What is the current status of trial NCT03124875?

This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2017-07-05. Estimated completion is 2021-01-05.

What conditions does trial NCT03124875 study?

This clinical trial studies the following conditions: Critical Limb Ischemia, Chronic Limb-Threatening Ischemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03124875?

The interventions under investigation include: LimFlow System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03124875?

This trial is sponsored by LimFlow, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03124875 being conducted?

This trial has 7 study locations across District of Columbia, Hawaii, Michigan, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial